...
首页> 外文期刊>Journal of cardiovascular risk >Plasma fibrinogen as a risk factor for restenosis after percutaneous transluminal renal angioplasty in patients with atherosclerotic renal artery stenosis.
【24h】

Plasma fibrinogen as a risk factor for restenosis after percutaneous transluminal renal angioplasty in patients with atherosclerotic renal artery stenosis.

机译:血浆纤维蛋白原是动脉粥样硬化性肾动脉狭窄患者经皮腔内肾血管成形术后再狭窄的危险因素。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: In contrast to those for coronary restenosis, the data regarding the risk factors for renal restenosis are limited. OBJECTIVE: To evaluate potential humoral risk factors for restenosis after percutaneous transluminal renal angioplasty (PTRA). METHODS: We studied 27 patients aged 54+/-10 years with atherosclerotic renal artery stenosis in a 1-year prospective follow-up. Restenosis (confirmed by angiography) occurred in eight patients 1-6 months after PTRA. We detected no Doppler ultrasound evidence of restenosis in 19 patients throughout 1 year. Blood studies were done before PTRA for all patients, at the time of diagnosis of restenosis and, for those without restenosis, after 1 year. including determinations of fibrinogen, lipids, platelets and leukocytes. RESULTS: The mean level of fibrinogen in patients who experienced restenosis was higher than that in those who did not (450+/-150 mg% versus 337+/-57 mg%, P < 0.01) and remained unchanged for both groups during follow-up. The other parameters did not differ between the groups before PTRA and did not change over time, with the exception of platelet count in patients who did not experience restenosis, which had decreased from 253+/-93G/l to 200+/-63G/l (P < 0.01) 1 year after PTRA. The logistic multiple regression analysis disclosed that an increment of fibrinogen level by 100 mg% was linked with an odds ratio for restenosis of 3.2 (95% confidence interval 1.1-9.8). CONCLUSIONS: Restenosis was associated with higher than normal levels of fibrinogen before PTRA. A high plasma fibrinogen level might play a role in the development of restenosis after PTRA.
机译:背景:与冠状动脉再狭窄相比,有关肾再狭窄危险因素的数据有限。目的:评估经皮腔内肾血管成形术(PTRA)后再狭窄的潜在体液危险因素。方法:我们在1年的前瞻性研究中对27例54 +/- 10岁的动脉粥样硬化性肾动脉狭窄患者进行了研究。再狭窄(经血管造影证实)发生在PTRA后1-6个月的8例患者中。我们在1年中未发现19例患者发生再狭窄的多普勒超声证据。对所有患者,在诊断为再狭窄时对所有患者进行PTRA之前的血液研究,对于没有再狭窄的患者,在1年后进行血液研究。包括测定纤维蛋白原,脂质,血小板和白细胞。结果:再狭窄患者中纤维蛋白原的平均水平高于未再狭窄患者(450 +/- 150 mg%对337 +/- 57 mg%,P <0.01),并且在随访期间两组均保持不变-向上。其他参数在PTRA之前各组之间无差异,并且没有随时间变化,除了未发生再狭窄的患者的血小板计数已从253 +/- 93G / l降至200 +/- 63G / PTRA后1年(P <0.01)。逻辑多元回归分析显示,纤维蛋白原水平增加100 mg%与再狭窄的比值比为3.2(95%置信区间1.1-9.8)相关。结论:再狭窄与PTRA前纤维蛋白原水平高于正常水平有关。血浆纤维蛋白原水平高可能在PTRA后发生再狭窄中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号